vs
Side-by-side financial comparison of P3 Health Partners Inc. (PIII) and GeneDx Holdings Corp. (WGS). Click either name above to swap in a different company.
P3 Health Partners Inc. is the larger business by last-quarter revenue ($384.8M vs $121.0M, roughly 3.2× GeneDx Holdings Corp.). GeneDx Holdings Corp. runs the higher net margin — -14.6% vs -19.6%, a 5.0% gap on every dollar of revenue. On growth, GeneDx Holdings Corp. posted the faster year-over-year revenue change (26.5% vs 3.8%). Over the past eight quarters, GeneDx Holdings Corp.'s revenue compounded faster (39.2% CAGR vs -0.5%).
P3 Health Partners Inc. is a population health management and value-based care services firm operating primarily in the United States. It partners with primary care providers and health systems to deliver coordinated, high-quality care for patient populations, especially Medicare Advantage beneficiaries, focusing on improving health outcomes and lowering unnecessary healthcare costs.
GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...
PIII vs WGS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $384.8M | $121.0M |
| Net Profit | $-75.5M | $-17.7M |
| Gross Margin | — | 69.6% |
| Operating Margin | -40.0% | -11.8% |
| Net Margin | -19.6% | -14.6% |
| Revenue YoY | 3.8% | 26.5% |
| Net Profit YoY | -28.8% | -424.9% |
| EPS (diluted) | $-23.08 | $-0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $384.8M | $121.0M | ||
| Q3 25 | $345.3M | $116.7M | ||
| Q2 25 | $355.8M | $102.7M | ||
| Q1 25 | $373.2M | $87.1M | ||
| Q4 24 | $370.7M | $95.6M | ||
| Q3 24 | $362.1M | $76.9M | ||
| Q2 24 | $379.2M | $70.5M | ||
| Q1 24 | $388.5M | $62.4M |
| Q4 25 | $-75.5M | $-17.7M | ||
| Q3 25 | $-31.6M | $-7.6M | ||
| Q2 25 | $-20.4M | $10.8M | ||
| Q1 25 | $-20.5M | $-6.5M | ||
| Q4 24 | $-58.6M | $5.4M | ||
| Q3 24 | $-46.5M | $-8.3M | ||
| Q2 24 | $-12.0M | $-29.2M | ||
| Q1 24 | $-18.7M | $-20.2M |
| Q4 25 | — | 69.6% | ||
| Q3 25 | — | 72.4% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 67.1% | ||
| Q4 24 | — | 69.2% | ||
| Q3 24 | — | 62.2% | ||
| Q2 24 | — | 60.9% | ||
| Q1 24 | — | 59.9% |
| Q4 25 | -40.0% | -11.8% | ||
| Q3 25 | -12.8% | -2.8% | ||
| Q2 25 | -9.6% | 8.7% | ||
| Q1 25 | -10.2% | -5.2% | ||
| Q4 24 | -37.4% | 9.2% | ||
| Q3 24 | -29.5% | -10.1% | ||
| Q2 24 | -8.3% | -15.0% | ||
| Q1 24 | -11.3% | -21.9% |
| Q4 25 | -19.6% | -14.6% | ||
| Q3 25 | -9.1% | -6.5% | ||
| Q2 25 | -5.7% | 10.5% | ||
| Q1 25 | -5.5% | -7.5% | ||
| Q4 24 | -15.8% | 5.7% | ||
| Q3 24 | -12.8% | -10.8% | ||
| Q2 24 | -3.2% | -41.4% | ||
| Q1 24 | -4.8% | -32.4% |
| Q4 25 | $-23.08 | $-0.59 | ||
| Q3 25 | $-9.67 | $-0.27 | ||
| Q2 25 | $-6.23 | $0.36 | ||
| Q1 25 | $-6.28 | $-0.23 | ||
| Q4 24 | $-23.13 | $0.25 | ||
| Q3 24 | $-15.70 | $-0.31 | ||
| Q2 24 | $-7.37 | $-1.10 | ||
| Q1 24 | $-7.86 | $-0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.0M | $171.3M |
| Total DebtLower is stronger | $228.4M | $54.5M |
| Stockholders' EquityBook value | $-155.2M | $308.2M |
| Total Assets | $656.6M | $523.7M |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.0M | $171.3M | ||
| Q3 25 | $37.7M | $155.1M | ||
| Q2 25 | $38.6M | $134.6M | ||
| Q1 25 | $40.1M | $159.2M | ||
| Q4 24 | $38.8M | $141.2M | ||
| Q3 24 | $63.0M | $116.5M | ||
| Q2 24 | $73.1M | $106.9M | ||
| Q1 24 | $27.3M | $112.9M |
| Q4 25 | $228.4M | $54.5M | ||
| Q3 25 | $252.8M | $54.8M | ||
| Q2 25 | $182.0M | $55.1M | ||
| Q1 25 | $171.1M | $55.5M | ||
| Q4 24 | $108.9M | $55.8M | ||
| Q3 24 | $133.2M | $56.1M | ||
| Q2 24 | $133.1M | $56.3M | ||
| Q1 24 | $118.1M | $56.3M |
| Q4 25 | $-155.2M | $308.2M | ||
| Q3 25 | $-18.7M | $292.3M | ||
| Q2 25 | $44.5M | $277.1M | ||
| Q1 25 | $63.3M | $257.4M | ||
| Q4 24 | $75.9M | $245.2M | ||
| Q3 24 | $120.5M | $204.5M | ||
| Q2 24 | $166.8M | $194.0M | ||
| Q1 24 | $146.6M | $207.2M |
| Q4 25 | $656.6M | $523.7M | ||
| Q3 25 | $683.6M | $493.9M | ||
| Q2 25 | $731.6M | $463.9M | ||
| Q1 25 | $783.9M | $446.4M | ||
| Q4 24 | $783.4M | $419.4M | ||
| Q3 24 | $833.3M | $408.8M | ||
| Q2 24 | $892.8M | $389.1M | ||
| Q1 24 | $855.9M | $394.5M |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | 4.09× | 0.20× | ||
| Q1 25 | 2.71× | 0.22× | ||
| Q4 24 | 1.43× | 0.23× | ||
| Q3 24 | 1.11× | 0.27× | ||
| Q2 24 | 0.80× | 0.29× | ||
| Q1 24 | 0.81× | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.7M | $-3.1M |
| Free Cash FlowOCF − Capex | — | $-7.4M |
| FCF MarginFCF / Revenue | — | -6.1% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.7M | $-3.1M | ||
| Q3 25 | $-15.4M | $15.8M | ||
| Q2 25 | $-16.6M | $10.4M | ||
| Q1 25 | $-33.5M | $10.2M | ||
| Q4 24 | $-57.2M | $-3.2M | ||
| Q3 24 | $-22.6M | $-4.4M | ||
| Q2 24 | $-10.2M | $-4.5M | ||
| Q1 24 | $-20.0M | $-16.4M |
| Q4 25 | — | $-7.4M | ||
| Q3 25 | — | $9.6M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $4.1M | ||
| Q4 24 | — | $-6.2M | ||
| Q3 24 | — | $-5.0M | ||
| Q2 24 | — | $-5.9M | ||
| Q1 24 | — | $-16.9M |
| Q4 25 | — | -6.1% | ||
| Q3 25 | — | 8.2% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | — | -6.6% | ||
| Q2 24 | — | -8.3% | ||
| Q1 24 | — | -27.0% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 5.3% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | 0.0% | 3.2% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 1.9% | ||
| Q1 24 | 0.0% | 0.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PIII
| Capitated Revenue | $366.2M | 95% |
| Health Care Patient Service | $18.6M | 5% |
| Health Care Care Coordination Management Fees | $2.7M | 1% |
WGS
| Diagnostic Test Third Party Insurance | $101.1M | 84% |
| Diagnostic Test Institutional Customers | $15.5M | 13% |
| Other | $3.4M | 3% |
